newsfilter
← Latest News
PR Newswire·

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Eleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis Pooled data from five Phase 3/3b trials showed that more than eight out of 10 patients who achieved complete skin clearance with bime